At the time of writing, Kymera Therapeutics Inc [KYMR] stock is trading at $34.37, up 2.75%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The KYMR shares have gain 4.50% over the last week, with a monthly amount drifted -2.22%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Kymera Therapeutics Inc [NASDAQ: KYMR] stock has seen the most recent analyst activity on March 13, 2025, when Citigroup initiated its Buy rating and assigned the stock a price target of $52. Previously, BTIG Research started tracking the stock with Buy rating on December 10, 2024, and set its price target to $60. On December 06, 2024, BMO Capital Markets initiated with a Market Perform rating and assigned a price target of $55 on the stock. Wells Fargo upgraded its rating to a Overweight but stick to its price target of $57 on December 02, 2024. Stephens initiated its recommendation with a Overweight and recommended $65 as its price target on November 18, 2024. In a note dated August 26, 2024, Wolfe Research upgraded an Outperform rating on this stock but restated the target price of $65.
For the past year, the stock price of Kymera Therapeutics Inc fluctuated between $29.07 and $53.27. Currently, Wall Street analysts expect the stock to reach $55.5 within the next 12 months. Kymera Therapeutics Inc [NASDAQ: KYMR] shares were valued at $34.37 at the most recent close of the market. An investor can expect a potential return of 61.48% based on the average KYMR price forecast.
Analyzing the KYMR fundamentals
According to Kymera Therapeutics Inc [NASDAQ:KYMR], the company’s sales were 47.07M for trailing twelve months, which represents an -84.56% plunge. Gross Profit Margin for this corporation currently stands at 0.89% with Operating Profit Margin at -5.45%, Pretax Profit Margin comes in at -4.76%, and Net Profit Margin reading is -4.76%. To continue investigating profitability, this company’s Return on Assets is posted at -0.23, Equity is -0.29 and Total Capital is -0.28. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.11.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 33.66 points at the first support level, and at 32.94 for the second support level. However, for the 1st resistance point, the stock is sitting at 35.04, and for the 2nd resistance point, it is at 35.70.
Ratios To Look Out For
It is important to note that Kymera Therapeutics Inc [NASDAQ:KYMR] has a current ratio of 7.53. Further, the Quick Ratio stands at 7.53, while the Cash Ratio is 1.77. Considering the valuation of this stock, the price to sales ratio is 47.42, the price to book ratio is 2.67.
Transactions by insiders
Recent insider trading involved Chiniara Ellen, Chief Legal Officer, that happened on Mar 03 ’25 when 2241.0 shares were sold. Chief Operating Officer, Chadwick Jeremy G completed a deal on Mar 03 ’25 to sell 1383.0 shares. Meanwhile, Chief Financial Officer Jacobs Bruce N. sold 7035.0 shares on Mar 03 ’25.
